Moxifloxacin + TobramycinThird Party Manufacturing in India

Moxifloxacin + Tobramycin works by providing synergetic, dual-mechanism antibacterial action against resistant ocular pathogens. Moxifloxacin targets bacterial DNA replication by blocking topoisomerase IV and DNA gyrase, stopping bacterial reproduction. Simultaneously, tobramycin sulfate binds irreversibly to the 30S ribosomal subunit of the bacterium, disrupting mRNA translation and causing faulty protein synthesis that compromises the cell membrane. Unlike single-antibiotic solutions, this formulation prevents mutant strain survival by covering both Gram-positive and Gram-negative targets. It is highly effective and well-tolerated.

Therapeutic Uses

• Resistant Bacterial Conjunctivitis: Eradicates severe ocular infections that display resistance to single-class antibiotic therapies.
• Bacterial Keratitis: Treats acute corneal infections, preventing tissue scarring and vision loss.
• Pre-Operative Prophylaxis: Sterilizes the ocular surface before invasive ophthalmic surgeries to prevent endophthalmitis.

Why Manufacturers Choose Moxifloxacin + Tobramycin

Opthalmologists favor this dual-antibiotic formulation to combat the rising incidence of drug-resistant ocular strains, ensuring consistent market demand. Utilizing Moxifloxacin + Tobramycin third party manufacturing in India allows pharma marketing firms to commercialize this complex combination efficiently. Our partner facilities are WHO-GMP certified, guaranteeing specialized chemical processing that preserves the potency of both the CAS 135738-90-2 active ingredient and the aminoglycoside component.